WGS · Genedx Holdings Corp. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $427.54M | $305.45M | $202.57M | $234.69M | $179.32M | - |
| Cost of Revenue | $129.37M | $111.05M | $112.56M | $261.44M | $175.30M | - |
| Gross Profit | $298.17M | $194.40M | $90.01M | ($26.75M) | $4.03M | - |
| R&D | $72.03M | $45.72M | $58.27M | $86.20M | $72.70M | - |
| SG&A | $150.82M | $101.11M | $133.75M | $203.33M | $100.74M | - |
| Total Operating Expenses | - | - | - | - | - | - |
| D&A | $9.60M | $7.90M | $19.70M | $59.31M | $11.73M | - |
| Operating Income | ($13.08M) | ($23.21M) | ($180.60M) | ($667.65M) | ($241.99M) | - |
| Interest Expense | - | - | - | $3.21M | $2.47M | - |
| Income Tax | ($116.0K) | ($343.0K) | ($926.0K) | ($49.05M) | $0 | - |
| Net Income | ($21.02M) | ($52.29M) | ($175.77M) | ($548.98M) | ($241.34M) | - |
| EPS - Basic | ($0.73) | ($1.94) | ($7.23) | ($53.79) | ($1552188.00) | - |
| EPS - Diluted | ($0.73) | ($1.94) | ($7.23) | ($53.79) | ($1552188.00) | - |
Balance Sheet
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $105.00M | $85.21M | $99.68M | $123.93M | $400.57M | $1.09M |
| Accounts Receivable | $74.37M | - | - | $42.63M | $33.34M | - |
| Inventory | $13.95M | $10.65M | $8.78M | $13.66M | $29.13M | - |
| Accounts Payable | $2.46M | $7.95M | $10.24M | $46.02M | $26.74M | - |
| Current Assets | $268.29M | $197.97M | $182.34M | $212.62M | $483.54M | $1.37M |
| Total Assets | $523.71M | $419.38M | $418.76M | $490.94M | $554.09M | $444.14M |
| Current Liabilities | $108.91M | $54.82M | $58.82M | $144.30M | $101.28M | $97.1K |
| Long-term Debt | $48.18M | $51.91M | $52.69M | $6.25M | $18.03M | - |
| Total Liabilities | $215.53M | $174.13M | $190.74M | $237.24M | $165.99M | $15.59M |
| Stockholders' Equity | $308.18M | $245.25M | $228.02M | $253.71M | $388.10M | $5.00M |
| Retained Earnings | ($1.37B) | ($1.35B) | ($1.30B) | ($1.12B) | ($575.44M) | ($192.2K) |
Cash Flow
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | $33.28M | ($28.50M) | ($180.15M) | ($319.15M) | ($93.13M) | - |
| Investing Cash Flow | ($61.52M) | ($30.13M) | ($43.73M) | ($141.33M) | ($31.97M) | - |
| Financing Cash Flow | $48.02M | $44.16M | $186.24M | $197.31M | $129.06M | - |
| CapEx | $19.02M | $5.49M | $5.25M | $7.16M | $24.09M | - |
| Free Cash Flow | $14.26M | ($33.99M) | ($185.40M) | ($326.31M) | ($117.22M) | - |
Ratios
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | 69.7% | 63.6% | 44.4% | -11.4% | 2.2% | - |
| Operating margin | -3.1% | -7.6% | -89.2% | -284.5% | -134.9% | - |
| EBITDA margin | -0.8% | -5.0% | -79.4% | -259.2% | -128.4% | - |
| Net margin | -4.9% | -17.1% | -86.8% | -233.9% | -134.6% | - |
| Free cash flow margin | 3.3% | -11.1% | -91.5% | -139.0% | -65.4% | - |
| FCF / Net income | -0.68 | 0.65 | 1.05 | 0.59 | 0.49 | - |
| R&D / Revenue | 16.8% | 15.0% | 28.8% | 36.7% | 40.5% | - |
| SG&A / Revenue | 35.3% | 33.1% | 66.0% | 86.6% | 56.2% | - |
| Effective tax rate | - | - | - | - | - | - |
| Return on assets | -4.0% | -12.5% | -42.0% | -111.8% | -43.6% | - |
| Return on equity | -6.8% | -21.3% | -77.1% | -216.4% | -62.2% | - |
| Return on invested capital | -2.9% | -6.2% | -50.8% | -202.9% | -47.1% | - |
| Liquidity | ||||||
| Current ratio | 2.46 | 3.61 | 3.10 | 1.47 | 4.77 | 14.12 |
| Quick ratio | 2.34 | 3.42 | 2.95 | 1.38 | 4.49 | 14.12 |
| Cash ratio | 0.96 | 1.55 | 1.69 | 0.86 | 3.95 | 11.27 |
| Leverage | ||||||
| Debt / Equity | 0.16 | 0.21 | 0.23 | 0.02 | 0.05 | - |
| Debt / Assets | 0.09 | 0.12 | 0.13 | 0.01 | 0.03 | - |
| Debt / EBITDA | - | - | - | - | - | - |
| Interest coverage | - | - | - | -208.2x | -97.8x | - |
| Equity multiplier | 1.70 | 1.71 | 1.84 | 1.94 | 1.43 | 88.83 |
| Liabilities / Assets | 0.41 | 0.42 | 0.46 | 0.48 | 0.30 | 0.04 |
| Efficiency | ||||||
| Asset turnover | 0.82 | 0.73 | 0.48 | 0.48 | 0.32 | - |
| Inventory turnover | 9.27 | 10.43 | 12.82 | 19.13 | 6.02 | - |
| Days sales outstanding | 63d | - | - | 66d | 68d | - |
| Days inventory outstanding | 39d | 35d | 28d | 19d | 61d | - |
| Days payable outstanding | 7d | 26d | 33d | 64d | 56d | - |
| Cash conversion cycle | 96d | - | - | 21d | 73d | - |
| Valuation | ||||||
| P / E | - | - | - | - | - | - |
| P / B | 12.1x | 8.4x | 0.3x | - | - | - |
| P / S | 8.7x | 6.8x | 0.3x | - | - | - |
| EV / EBITDA | - | - | - | - | - | - |
| Growth | ||||||
| Revenue growth (YoY) | 40.0% | 50.8% | -13.7% | 30.9% | - | - |
| Revenue CAGR (3y) | 22.1% | 19.4% | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - |
| Gross profit growth (YoY) | 53.4% | 116.0% | - | - | - | - |
| Operating income growth (YoY) | 43.7% | 87.1% | 73.0% | -175.9% | - | - |
| Net income growth (YoY) | 59.8% | 70.3% | 68.0% | -127.5% | - | - |
| EPS growth (YoY) | 62.4% | 73.2% | 86.6% | 100.0% | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - |
| FCF growth (YoY) | - | 81.7% | 43.2% | -178.4% | - | - |
| FCF CAGR (5y) | - | - | - | - | - | - |
| Book value growth (YoY) | 25.7% | 7.6% | -10.1% | -34.6% | 7662.1% | - |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2025-12-31.
Business segments
$427.54M totalGene Dx$423.09M · 99.0%
All Other Segments$4.45M · 1.0%
Product / service
$843.18M totalDiagnostic Test$416.67M · 49.4%
Diagnostic Test Third Party Insurance$345.24M · 40.9%
Diagnostic Test Institutional Customers$69.05M · 8.2%
Product And Service Other$10.87M · 1.3%
Diagnostic Test Self Pay$1.36M · 0.2%
Stability scores
Altman Z′
FY 2025 · bankruptcy risk
-0.67
Distress
Private-firm variant - uses book equity instead of market cap. > 2.90 safe · 1.23-2.90 grey · < 1.23 distress.
Piotroski F-score
FY 2025 · 9-point quality
6/9
Neutral
- ✗Net income positive
- ✓Operating cash flow positive
- ✓ROA improved YoY
- ✓Cash flow > net income
- ✓Long-term debt decreased
- ✗Current ratio improved
- ✗No share dilution
- ✓Gross margin improved
- ✓Asset turnover improved
Peer comparison
Same SIC group: Services-Health Services
Comparing GeneDx Holdings Corp. against the 5 most active filers in the same SIC group.